arsenic trioxide has been researched along with Abnormalities, Autosome in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, M; Liao, C; Shen, D; Shen, H; Song, H; Tang, Y; Wang, Y; Zhang, J; Zhu, H | 1 |
| Campbell, LJ; Derkach, A; Epstein-Peterson, ZD; Geyer, S; Iland, H; Kohlschmidt, J; Larson, RA; Mrózek, K; Park, JH; Poiré, X; Powell, BL; Rajeeve, S; Stein, EM; Stock, W; Stone, RM; Tallman, MS; Zhang, Y | 1 |
| Alt, F; Backes, N; Bender, H; Brockmann, MA; Burhenne, J; Faber, J; Filipski, K; Fresnais, M; Glaser, M; Harter, PN; Huprich, S; Lehmann, N; Neu, MA; Paret, C; Pietsch, T; Roth, L; Russo, A; Seidmann, L; Sommer, C; Wagner, W; Wingerter, A | 1 |
| Bergua, J; Boluda, B; Brunet, S; Calasanz, MJ; Cervera, J; Chillón, MC; de laSerna, J; Esteve, J; Fernández, I; Gil, C; González-Campos, J; González-Sanmiguel, JD; Holowiecka, A; Krsnik, I; Labrador, J; Lowenberg, B; Luño, E; Manso, F; Montesinos, P; Moreno, MJ; Pérez-Encinas, M; Ribera, JM; Salamero, O; Sanz, MA; Sobas, M; Tormo, M; Vellenga, E | 1 |
| Chen, Z; Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Tong, Y; Wang, Y; Ye, X | 1 |
| Bhattacharya, S; Chakraborty, A; Chattopadhyay, A; Srivastava, R | 1 |
| Lo-Coco, F; Testa, U | 1 |
| Banerjee, P; Belon, P; Bhattacharyya, SS; Khuda-Bukhsh, AR; Naoual, B; Pathak, S | 1 |
| Haferlach, T | 1 |
| Trivedi, SP; Yadav, KK | 1 |
| Rao, MV; Tiwari, H | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Hajhashemi, M; Mozdarani, H; Yaghmaie, M | 1 |
| Chim, CS; Kam, S; Kwong, YL; Lam, CC; Man, C; Wong, KF | 1 |
| Meng, R; Yang, BF; Zhao, DY; Zhou, J | 1 |
| Patlolla, AK; Tchounwou, PB | 1 |
| Hess, U | 1 |
| Campbell, LJ; Catalano, A; Dawson, MA; Iland, H; Opat, S; Schwarer, A; Somana, K | 1 |
| Gebel, T | 1 |
| Bukhsh, AR; Datta, S; Mallick, P | 2 |
3 review(s) available for arsenic trioxide and Abnormalities, Autosome
| Article | Year |
|---|---|
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Topics: Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Disseminated Intravascular Coagulation; DNA-Binding Proteins; fms-Like Tyrosine Kinase 3; Hemorrhagic Disorders; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukocyte Count; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Prognosis; Risk Factors; Tandem Repeat Sequences; Treatment Outcome; Tretinoin; Tumor Protein p73; Tumor Suppressor Proteins | 2016 |
Molecular genetic pathways as therapeutic targets in acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Chromosome Aberrations; Genetic Markers; Humans; Karyotyping; Leukemia, Myeloid, Acute; Models, Genetic; Mutation; Oxides; Proto-Oncogene Proteins c-kit; Transcription, Genetic; Tretinoin | 2008 |
[The plasma cell myeloma--molecular pathogenesis and target therapies].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors | 2006 |
1 trial(s) available for arsenic trioxide and Abnormalities, Autosome
| Article | Year |
|---|---|
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Translocation, Genetic; Tretinoin; Young Adult | 2013 |
16 other study(ies) available for arsenic trioxide and Abnormalities, Autosome
| Article | Year |
|---|---|
A Novel NUP98/RARG Gene Fusion in Pediatric Acute Myeloid Leukemia Resembling Acute Promyelocytic Leukemia.
Topics: Adult; Arsenic Trioxide; Child; Chromosome Aberrations; Gene Fusion; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Nuclear Pore Complex Proteins | 2022 |
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Chromosome Aberrations; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Prognosis | 2022 |
Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor.
Topics: Adult; Arsenic Trioxide; Base Sequence; Brain; Brain Neoplasms; Cell Line, Tumor; Child, Preschool; Chromosome Aberrations; DNA Methylation; Female; Germ-Line Mutation; Humans; Insulin-Like Growth Factor I; Molecular Targeted Therapy; Neoplasms, Neuroepithelial; Principal Component Analysis; Pyrimidines; Receptor, Notch1; Sulfones; Transcriptome; Tumor Suppressor Protein p53 | 2019 |
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
Topics: Abnormal Karyotype; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Recurrence; Treatment Outcome; Young Adult | 2019 |
Differential in vivo genotoxicity of arsenic trioxide in glutathione depleted mouse bone marrow cells: expressions of Nrf2/Keap1/P62.
Topics: Acetylcysteine; Adaptor Proteins, Signal Transducing; Animals; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Buthionine Sulfoximine; Chromatids; Chromosome Aberrations; Cytoskeletal Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Gene Expression Regulation, Neoplastic; Glutamate-Cysteine Ligase; Glutathione; Kelch-Like ECH-Associated Protein 1; Male; Membrane Glycoproteins; Mice; Mutagens; Neoplasm Proteins; NF-E2-Related Factor 2; Nuclear Pore Complex Proteins; Oxides | 2015 |
Comparative efficacy of two microdoses of a potentized homeopathic drug, arsenicum album, to ameliorate toxicity induced by repeated sublethal injections of arsenic trioxide in mice.
Topics: Acid Phosphatase; Alkaline Phosphatase; Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Catalase; Chromosome Aberrations; Chronic Disease; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Glutathione; Lipid Metabolism; Male; Materia Medica; Mice; Mitotic Index; Oxides; Spermatozoa; Succinate Dehydrogenase; Transaminases; Treatment Outcome | 2008 |
Chromosomal aberrations in a fish, Channa punctata after in vivo exposure to three heavy metals.
Topics: Animals; Arsenic Trioxide; Arsenicals; Carcinogens; Chromosome Aberrations; Copper Sulfate; Fishes; Mercuric Chloride; Metals, Heavy; Mutagenicity Tests; Oxides; Water Pollutants, Chemical | 2009 |
Curcumin supplementation protects from genotoxic effects of arsenic and fluoride.
Topics: Adult; Aneuploidy; Antimutagenic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Cells, Cultured; Chromosome Aberrations; Chromosome Breakage; Comet Assay; Curcumin; DNA Damage; Humans; Lymphocytes; Oxides; Phytohemagglutinins; Sodium Fluoride; Young Adult | 2010 |
Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Chromosome Aberrations; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Tumor Cells, Cultured | 2012 |
Atypical blasts and bone marrow necrosis associated with near-triploid relapse of acute promyelocytic leukemia after arsenic trioxide treatment.
Topics: Adult; Arsenic Trioxide; Arsenicals; Biopsy; Bone Marrow; Chromosome Aberrations; Fatal Outcome; Female; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Necrosis; Oxides; Ploidies; Recurrence | 2002 |
A case of M2a with complex chromosome aberrations obtained complete remission through modified As2O3 medication.
Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Chromosome Aberrations; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Oxides; Remission Induction | 2004 |
Cytogenetic evaluation of arsenic trioxide toxicity in Sprague-Dawley rats.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Chromosome Aberrations; Growth Inhibitors; Male; Micronucleus Tests; Mitosis; Oxides; Rats; Rats, Sprague-Dawley | 2005 |
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Base Sequence; Bone Marrow; Chromosome Aberrations; Clinical Trials as Topic; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; DNA Mutational Analysis; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mutant Chimeric Proteins; Neoplasm Proteins; Oxides; Receptors, Retinoic Acid; Registries; Remission Induction; Retinoic Acid Receptor alpha; RNA, Messenger; Sequence Deletion; Tretinoin | 2007 |
Suppression of arsenic-induced chromosome mutagenicity by antimony.
Topics: Animals; Antimony; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Line; Cell Survival; Chlorides; Chromosome Aberrations; Chromosomes; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Micronucleus Tests; Mutagenesis; Mutagenicity Tests; Mutagens; Oxides | 1998 |
Efficacy of a potentized homoeopathic drug (Arsenicum Album-30) in reducing genotoxic effects produced by arsenic trioxide in mice: comparative studies of pre-, post- and combined pre- and post-oral administration and comparative efficacy of two microdose
Topics: Administration, Oral; Analysis of Variance; Animals; Antidotes; Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chromosome Aberrations; Disease Models, Animal; Dose-Response Relationship, Drug; Homeopathy; Mice; Mitotic Index; Mutagenicity Tests; Oxides; Poisoning; Reference Values | 1999 |
Efficacy of a potentized homoeopathic drug (Arsenicum Album-30) in reducing genotoxic effects produced by arsenic trioxide in mice: II. Comparative efficacy of an antibiotic, actinomycin D alone and in combination with either of two microdoses.
Topics: Animals; Anti-Bacterial Agents; Arsenic Trioxide; Arsenicals; Chromosome Aberrations; Dactinomycin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Homeopathy; Male; Mice; Micronucleus Tests; Mitotic Index; Oxides; Random Allocation; Spermatozoa; Transcription, Genetic | 1999 |